306 related articles for article (PubMed ID: 4045923)
1. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
2. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
3. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
5. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
Lammek B; Bankowski K; Misicka A; Manning M; Seto J; Sawyer WH
J Med Chem; 1989 Jan; 32(1):244-7. PubMed ID: 2909737
[TBL] [Abstract][Full Text] [Related]
6. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
Bankowski K; Manning M; Haldar J; Sawyer WH
J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
[TBL] [Abstract][Full Text] [Related]
7. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
8. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
9. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
[TBL] [Abstract][Full Text] [Related]
10. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
11. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
[TBL] [Abstract][Full Text] [Related]
13. [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
Lowbridge J; Manning M; Haldar J; Sawyer WH
J Med Chem; 1978 Mar; 21(3):313-5. PubMed ID: 628009
[TBL] [Abstract][Full Text] [Related]
14. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
15. [1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
Lowbridge J; Manning M; Haldar J; Sawyer W
J Med Chem; 1977 Sep; 20(9):1173-6. PubMed ID: 926117
[TBL] [Abstract][Full Text] [Related]
16. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.
Lowbridge J; Manning M; Seto J; Haldar J; Sawyer WH
J Med Chem; 1979 May; 22(5):565-9. PubMed ID: 458806
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs.
Schwartz J; Liard JF; Ott C; Cowley AW
Am J Physiol; 1985 Nov; 249(5 Pt 2):H1001-8. PubMed ID: 3840655
[TBL] [Abstract][Full Text] [Related]
18. Desensitization of renal vasopressin-stimulated adenylate cyclase by a vasopressor and antidiuretic antagonist, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-ethyl)-D-tyrosine, 4-valine]arginine vasopressin.
Chang P; Kimura K
Biochem Biophys Res Commun; 1987 Apr; 144(2):770-8. PubMed ID: 3579941
[TBL] [Abstract][Full Text] [Related]
19. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
Pang CC; Leighton KM
Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
[TBL] [Abstract][Full Text] [Related]
20. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
